International Parkinson's Disease Genetics Consortium

Introduction

<div class="infobox infobox-institution">
{| class="infobox-table"
| colspan="2" class="infobox-header" | International Parkinson's Disease Genetics Consortium (IPDGC)
|-
| Founded | 2009
|-
| Type | International Research Consortium
|-
| Focus | Parkinson's disease genetics and genomics
|-
| Membership | 100+ institutions globally
|-
| Website | [pdgenetics.org](https://pdgenetics.org)
|}
</div>

Overview

Introduction

<div class="infobox infobox-institution">
{| class="infobox-table"
| colspan="2" class="infobox-header" | International Parkinson's Disease Genetics Consortium (IPDGC)
|-
| Founded | 2009
|-
| Type | International Research Consortium
|-
| Focus | Parkinson's disease genetics and genomics
|-
| Membership | 100+ institutions globally
|-
| Website | [pdgenetics.org](https://pdgenetics.org)
|}
</div>

Overview

The International Parkinson's Disease Genetics Consortium (IPDGC) is a global network of researchers dedicated to identifying genetic factors that contribute to Parkinson's disease risk, progression, and therapeutic response["@global2022"]. Founded in 2009, the consortium coordinates large-scale genetic studies across diverse populations worldwide, making it one of the most influential collaborative efforts in neurodegenerative disease research.

The IPDGC has transformed our understanding of Parkinson's disease genetics through unprecedented collaboration["@ipdgc2019"]. By pooling data and samples from hundreds of researchers across dozens of countries, the consortium has identified over 100 genetic risk loci for Parkinson's disease, discovered novel disease-causing mutations, and established resources that enable precision medicine approaches for PD treatment.

The consortium's work has fundamental implications for understanding disease mechanisms, identifying therapeutic targets, and eventually developing disease-modifying therapies. Genetic discoveries provide crucial insights into the biological pathways involved in Parkinson's disease pathogenesis, including alpha-synuclein aggregation, mitochondrial dysfunction, lysosomal impairment, and neuroinflammation["@singleton2014"].

Mission and Strategic Goals

Core Objectives

The IPDGC pursues several interconnected missions:

Discovery of Genetic Risk Factors
The consortium conducts genome-wide association studies (GWAS), whole exome sequencing (WES), and whole genome sequencing (WGS) to identify both common and rare genetic variants influencing Parkinson's disease risk. Each discovery provides potential insight into disease biology and therapeutic targets[@farrer2006].

Understanding Disease Mechanisms
By characterizing how genetic variants contribute to disease pathogenesis, IPDGC researchers elucidate the molecular mechanisms underlying Parkinson's disease. This knowledge guides drug development and helps identify promising therapeutic targets.

Enabling Precision Medicine
Genetic stratification of patients enables development of targeted therapies for specific genetic subtypes. The consortium develops and validates genetic testing approaches that can guide clinical care and clinical trial enrollment[@katz2023].

Data Sharing and Resource Development
The IPDGC maintains shared data resources that accelerate discovery by enabling researchers worldwide to analyze pooled datasets. This approach maximizes the scientific return on research investment.

Research Programs and Initiatives

Genome-Wide Association Studies (GWAS)

The IPDGC has conducted the largest Parkinson's disease GWAS to date[@nalls2019], identifying:

• Over 100 risk loci across the genome
• Novel pathways including lysosomal function, mitochondrial biology, and immune regulation
• Population-specific risk factors through diverse cohort analysis
• Genetic correlation with other neurodegenerative disorders

Whole Exome Sequencing (WES)

Rare genetic variants with large effect sizes provide particularly powerful insights into disease biology. The IPDGC WES program has:

• Analyzed over 20,000 PD cases and controls
• Identified pathogenic mutations in known PD genes
• Discovered novel genes including ATP13A2, DNAJC13, and others
• Characterized mutation spectrum in diverse populations

Whole Genome Sequencing (WGS)

Comprehensive WGS enables detection of all variant types:

• Structural variants including large copy number variations
• Non-coding regulatory variants
• Mitochondrial DNA variants
• Complex haplotypes

Global Parkinson's Genetics Program (GP2)

The Global Parkinson's Genetics Program represents the largest single initiative in PD genetics[@global2022]. This $150 million program aims to:

• Genotype 150,000+ samples from diverse populations worldwide
• Establish reference datasets for genetic interpretation
• Enable mechanistic studies in under-represented populations
• Support clinical translation through genetic testing infrastructure

• African populations (iPDGC Africa)
• Asian populations across East, South, and Southeast Asia
• Latin American populations
• Middle Eastern populations

NeuroXchip Development

The consortium developed NeuroXchip, a custom genotyping array optimized for neurodegenerative disease research[@blauwendraat2020]. This specialized chip includes:

• Known risk variants from GWAS
• Rare variants in PD genes
• Variants in related neurodegenerative disease genes
• Ancestry-informative markers

Genetic Discoveries and Breakthroughs

Monogenic Parkinson's Disease Genes

The IPDGC has contributed to characterizing genes causing familial Parkinson's disease:

SNCA (Alpha-Synuclein)
The first gene linked to hereditary Parkinson's disease[@singleton2014]. Multiplications cause autosomal dominant PD with dementia. Point mutations (A53T, A30P, E46K) cause Lewy body disease. The discovery established that alpha-synuclein aggregation is central to PD pathogenesis.

LRRK2 (Leucine-Rich Repeat Kinase 2)
The most common cause of autosomal dominant Parkinson's disease. The G2019S mutation accounts for up to 5% of PD in some populations[@schaller2015]. LRRK2 inhibitors are in clinical development.

GBA (Glucocerebrosidase)
GBA mutations represent the most significant genetic risk factor for PD identified to date[@giannoccaro2019]. Carriers have 5-6x increased risk. The link between Gaucher disease and PD established the importance of lysosomal dysfunction in PD pathogenesis.

PARKIN and PINK1
These genes cause autosomal recessive young-onset Parkinson's disease. They are critical for mitochondrial quality control (mitophagy), establishing mitochondrial dysfunction as a key PD mechanism.

ATP13A2, DNAJC13, and VPS35
Additional genes identified through IPDGC research, each revealing novel biological pathways.

Risk Genes from GWAS

The IPDGC has systematically mapped common genetic variants influencing PD risk[@pankratz2009]. Key loci include:

| Gene/Locus | Mechanism | Therapeutic Target |
|------------|-----------|-------------------|
| SNCA | Alpha-synuclein aggregation | Anti-aggregation drugs |
| LRRK2 | Kinase activity | LRRK2 inhibitors |
| GBA | Lysosomal function | Gene therapy, chaperones |
| HLA-DRA | Immune regulation | Anti-inflammatory drugs |
| MAPT | Tau pathology | Anti-tau therapies |
| GCH1 | Dopamine synthesis | DOPA supplementation |

Population Genetics and Diversity

Addressing Global Diversity

A major IPDGC priority is understanding Parkinson's disease genetics across all populations[@global2022]. Prior to GP2, over 80% of PD genetics research involved European-ancestry subjects, missing critical insights from other populations.

Population-Specific Studies

African Populations
iPDGC Africa studies African cohorts to identify novel risk factors and understand the genetic architecture in these understudied populations. Founder mutations and unique risk factors are being characterized.

Ashkenazi Jewish Population
Studies in this well-characterized founder population have identified unique genetic factors and validated known risk alleles[@plot2012].

Asian Populations
Research across East Asia, South Asia, and Southeast Asia has identified both shared and population-specific risk factors. LRRK2 variants show different frequency patterns compared to European populations.

Collaborative Network Structure

Regional Organization

The IPDGC coordinates research through regional hubs:

| Region | Lead Institutions |
|--------|-------------------|
| North America | NIH, Mayo Clinic, Columbia University |
| Europe | Karolinska Institute, University College London |
| Asia | National University of Singapore, Tokyo University |
| Australia | University of Sydney, University of Queensland |

Key Partnerships

Funding Organizations

• Michael J. Fox Foundation (MJFF)
• National Institutes of Health (NIH)
• Parkinson's UK
• Cure Parkinson's
• The Chan Zuckerberg Initiative

• Pharmaceutical companies collaborating on clinical trials
• Biotech partnerships for therapeutic development
• Genetic testing companies for clinical translation

Related Consortia

The IPDGC coordinates with other specialized consortia:

• GBA-PD Consortium: Focuses on glucocerebrosidase biology
• LRRK2 Consortium: LRRK2-specific research
• PD Dementia Genetics Consortium: Genetics of PD dementia
• Progeny Consortium: Early-onset PD genetics

Data Resources and Infrastructure

IPDGC Data Repository

The consortium maintains shared data resources:

• GWAS summary statistics (publicly available)
• WES/WGS variant calls (controlled access)
• Phenotype data with standardized definitions
• Replication network for validation studies

Analysis Infrastructure

Standardized analysis pipelines enable:

• Quality control and imputation
• Association testing
• Meta-analysis
• Polygenic risk score calculation

Clinical Translation

Genetic Testing Guidelines

The IPDGC has developed guidelines for clinical genetic testing in PD:

• Criteria for testing symptomatic individuals
• Testing in at-risk family members
• Interpretation of variants of uncertain significance
• Counseling recommendations

Precision Medicine Initiatives

Genetic stratification is enabling:

• Clinical trial enrichment: Selecting patients with specific genetic subtypes
• Stratified therapeutics: Targeting treatments to genetic subgroups
• Prevention studies: Identifying at-risk individuals for early intervention

Impact and Achievements

Scientific Output

The consortium has produced:

• 100+ high-impact publications in leading journals
• 90+ genetic risk loci identified
• 200+ research institutions participating globally
• 150,000+ samples collected and analyzed

Discovery Impact

Genetic discoveries have:

• Established alpha-synuclein aggregation as central to PD pathogenesis
• Identified lysosomal dysfunction as a key mechanism
• Revealed immune system involvement in PD
• Enabled development of LRRK2 inhibitors in clinical trials

Training and Capacity Building

The consortium supports:

• Training of next-generation PD genetics researchers
• Capacity building in under-resourced settings
• Data sharing infrastructure development

Future Directions

Strategic Priorities

The IPDGC has outlined ambitious future goals:

Expand Diversity

• Complete GP2 genotyping of 150,000+ samples
• Establish research infrastructure in Africa, Latin America, and South Asia

• Connect genetic variants to biological pathways
• Support functional studies and model development

• Support clinical development of targeted therapies
• Establish clinical genetic testing infrastructure

Emerging Technologies

The consortium is preparing for:

• Single-cell genomics approaches
• Functional genomics and CRISPR screens
• Multi-omics integration
• Machine learning for variant interpretation

See Also

• [Parkinson's Disease](/diseases/parkinsons-disease)](/proteins/parkin)
• [Alpha-Synuclein](/proteins/alpha-synuclein)](/proteins)
• [LRRK2 Gene](/genes/lrrk2)](/genes)
• [GBA Gene](/genes/gba)](/genes)
• [Michael J. Fox Foundation](/institutions/michael-j-fox-foundation)](/institutions)
• [Karolinska Institute](/institutions/karolinska-institute)

References